Document Detail

Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics.
MedLine Citation:
PMID:  15624336     Owner:  NLM     Status:  MEDLINE    
Thromboembolism is the largest cause of morbidity and mortality in the western world, yet oral anticoagulation is currently available only with vitamin K antagonists--most often, warfarin. Warfarin has been used for treatment of thrombotic disease for about 50 years. However, despite its widespread use, it is associated with several limitations, such as varied patient response, a narrow therapeutic window, numerous drug and food interactions, and need for frequent therapeutic monitoring. In addition, its full anticoagulant effect usually takes at least 4-5 days after the start of therapy or any dosage change, and it has a slow offset of therapy. A new oral anticoagulant, ximelagatran, has considerable advantages compared with warfarin. The agent requires no therapeutic monitoring, has a wide therapeutic window, and is not known to interact with food or drugs. The advantages ximelagatran brings to clinical practice should be a welcome addition to the options for management of thrombotic disease.
Paul P Dobesh
Related Documents :
14613246 - Porosity of porcine bladder acellular matrix: impact of acm thickness.
12093316 - Food-drug interactions.
3111026 - Oltipraz: administration with food increases its anti-schistosomal activity.
1195276 - Structure-activity relationships of antiarrhythmic 6-substituted decahydroisoquinolines.
1303036 - The state of food hygiene and foodborne diseases: requirements for the future.
23767366 - Validation of the soleris nf-tvc method for determination of total viable count in a va...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  24     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-12-30     Completed Date:  2005-05-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  169S-178S     Citation Subset:  IM    
Division of Pharmacy Practice, St Louis College of Pharmacy, St Louis, Missouri 63110, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Azetidines / pharmacokinetics*,  pharmacology*,  therapeutic use
Clinical Trials, Phase III as Topic
Cross-Over Studies
Meta-Analysis as Topic
Reg. No./Substance:
0/Azetidines; 0/Benzylamines; 0/ximelagatran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of macrophages from lymphoma-bearing mice by liposome mediated intraperitoneal IL-2 and I...
Next Document:  The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism.